MetaCap

Century Therapeutics Inc. (IPSC)

NASDAQ: IPSCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.17-0.155 (-11.74%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IPSC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$211.56M
EPS (TTM)
-$0.64
52-week range
0.48 – 3.04
Day range
1.16 – 1.32
Volume / Avg
916.11K / 759.69K
Beta
—

52-week range

$0.48$3.04

IPSC stock today

Century Therapeutics (IPSC) closed at $1.17 on Nov 20, down 11.74% (-$0.155), versus the S&P 500's 3.70% decline. Shares are 61.7% below their 52-week high of $3.04, set on Mar 10, 2026 and 142.7% above the 52-week low of $0.48, in the middle of the past year's range. IPSC is up 17.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 137.8%.

Century Therapeutics has posted a net loss over the last twelve months (EPS of -$0.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Century Therapeutics

Company profile

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
Headquarters
Philadelphia, PA
Employees
78
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Century Therapeutics generated $109.2 million in revenue, up 1556.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Century Therapeutics reported a net loss of $9.6 million, compared with a loss of $126.6 million a year earlier. Operating margin was -15.8%.

Century Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$109.16M$6.59M$2.23M$5.20M—
Growth+1556.76%+194.81%-57.01%——
Net income$-9.58M$-126.57M$-136.67M$-130.93M$-95.82M
EPS (diluted)$-0.14$-1.61$-2.30$-2.96$-2.96

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$4.75+307.73%

  • Strong buy 1
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.11 vs $-0.12
Surprise
+8.33%

IPSC news

All IPSC news

Century Therapeutics peers

Health Care sector
IPSC peer companies
CompanyPrice% ChgMarket capCompare
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs IPSC
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs IPSC
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs IPSC
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs IPSC
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs IPSC
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs IPSC
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs IPSC
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs IPSC

Indexes, lists and sector

Century Therapeutics stock FAQ

What is Century Therapeutics's stock price today?

IPSC last traded at $1.17 as of Nov 20, 4:00 PM EST, down 11.74% on the day. Prices are delayed at least 15 minutes.

Who is Century Therapeutics's CEO?

Dr. Brent Pfeiffenberger M.B.A., Pharm.D. is the chief executive officer of Century Therapeutics Inc., which has about 78 employees.

What is the IPSC 52-week high?

The 52-week high for IPSC is $3.04 and the 52-week low is $0.48. The stock is currently 61.7% below its high.

Compare IPSC